1
Short title
1 Short title
This order may be cited as the Poisons (Application of Uniform Standard) Order 2021 .
//
© 2026 Zoe. All rights reserved.
Zoe is a legal information platform. Always consult the Federal Register of Legislation for authoritative text.
Tasmania regulation
This Order amends how Tasmania applies the national "Uniform Standard" for poisons by replacing the Schedule 8 entry for cannabis. It treats cannabis prepared, packed, supplied or imported for human therapeutic use as covered when produced or brought in under Commonwealth narcotic‑drugs or therapeutic‑goods laws, and separately permits licensed research uses. It also revokes the 2018 Order. It affects producers, importers, therapeutic‑goods suppliers and licence holders by aligning local poison controls with Commonwealth regimes.
Want the full deep dive?
Zoe can write the in-depth analysis on top of the summary above: how it works, who it affects and what each part actually does.
Direct links to the current provisions in Poisons (Application of Uniform Standard) Order 2021.
This order may be cited as the Poisons (Application of Uniform Standard) Order 2021 .
This order takes effect on the day on which its making is notified in the Gazette.
The Acts Interpretation Act 1931 applies to the interpretation of this order as if this order were by-laws.
The Uniform Standard, in its application to Tasmania, is amended by omitting from Schedule 8 the item relating to cannabis and adding the following item:
| Cannabis (including seeds, extracts, resins and the plant, and any part of the plant) when – |
(a) prepared or packed for human therapeutic use, when –
(i) cultivated or produced, or in products manufactured, in accordance with the Narcotic Drugs Act 1967 of the Commonwealth; or
(ii) for use in products manufactured in accordance with the Narcotic Drugs Act 1967 of the Commonwealth; or
(iii) imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the Therapeutic Goods Act 1989 of the Commonwealth; or
(iv) in therapeutic goods, supplied in accordance with the Therapeutic Goods Act 1989 of the Commonwealth, except when –
(A) it is in a product to which item 4, 8, 10, 11 or 12 of Schedule 5A to the Therapeutic Goods Regulations 1990 of the Commonwealth applies; or
(B) the therapeutic goods are separately specified in the nabiximols entry in this Schedule; or
(C) the cannabidiol entry in Schedule 3, or Schedule 4, applies to the therapeutic goods; or
(D) [Clause 4 Amended by S.R. 2026, No. 6, Applied:11 Feb 2026] the therapeutic goods contain hemp seed oil containing 75mg/kg or less of cannabidiol and 10mg/kg or less of tetrahydrocannabinols; or
(b) used in research or development of products for human therapeutic use, where –
(i) it is used by the holder of a licence granted and in force under section 16 of the Poisons Act 1971 or regulation 11 of the Poisons Regulations 2018; and
(ii) the conditions of the licence specifically authorise the use.
The legislation specified in Schedule 1 is revoked.
| Poisons (Application of Uniform Standard) Order 2018 (No. 90 of 2018) |
Displayed and numbered in accordance with the Rules Publication Act 1953.
Notified in the Gazette on 28 July 2021
This order is administered in the Department of Health.
Sourced from Tasmanian Legislation Online (legislation.tas.gov.au), CC BY 4.0.
This order may be cited as the Poisons (Application of Uniform Standard) Order 2021 .
This order takes effect on the day on which its making is notified in the Gazette.
The Acts Interpretation Act 1931 applies to the interpretation of this order as if this order were by-laws.
The Uniform Standard, in its application to Tasmania, is amended by omitting from Schedule 8 the item relating to cannabis and adding the following item:
| Cannabis (including seeds, extracts, resins and the plant, and any part of the plant) when – |
(a) prepared or packed for human therapeutic use, when –
(i) cultivated or produced, or in products manufactured, in accordance with the Narcotic Drugs Act 1967 of the Commonwealth; or
(ii) for use in products manufactured in accordance with the Narcotic Drugs Act 1967 of the Commonwealth; or
(iii) imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the Therapeutic Goods Act 1989 of the Commonwealth; or
(iv) in therapeutic goods, supplied in accordance with the Therapeutic Goods Act 1989 of the Commonwealth, except when –
(A) it is in a product to which item 4, 8, 10, 11 or 12 of Schedule 5A to the Therapeutic Goods Regulations 1990 of the Commonwealth applies; or
(B) the therapeutic goods are separately specified in the nabiximols entry in this Schedule; or
(C) the cannabidiol entry in Schedule 3, or Schedule 4, applies to the therapeutic goods; or
(D) the therapeutic goods contain hemp seed oil containing 75mg/kg or less of cannabidiol and 10mg/kg or less of tetrahydrocannabinols; or
(b) used in research or development of products for human therapeutic use, where –
(i) it is used by the holder of a licence granted and in force under section 16 of the Poisons Act 1971 or regulation 11 of the Poisons Regulations 2018; and
(ii) the conditions of the licence specifically authorise the use.
The legislation specified in Schedule 1 is revoked.
Clause 5
| Poisons (Application of Uniform Standard) Order 2018 (No. 90 of 2018) |
Displayed and numbered in accordance with the Rules Publication Act 1953.
Notified in the Gazette on 28 July 2021
This order is administered in the Department of Health.